

Qinghua Hu, Ph.D.

Professor of School of Life Science and
Technology
China Pharmaceutical University
Email: huqh@cpu.edu.cn



中國藥科大學
CHINA PHARMACEUTICAL UNIVERSITY

RESEARCH

Dean/Professor China Pharmaceutical University School of Life Sciences and Technology	2023 - Current
Professor China Pharmaceutical University School of Pharmacy	2021 - 2023
Associate Professor China Pharmaceutical University School of Pharmacy	2014 - 2021
Lecturer China Pharmaceutical University School of Pharmacy	2011 - 2014
Postgraduate/Doctor Nanjing University School of Life Sciences <i>Advisor: Prof. Kong Lingdong</i>	2006 - 2011
Bachelor Nanjing University Kuan Yaming College <i>Advisor: Prof. Qiao Weihong</i>	2002 - 2006

PUBLICATIONS

1. Fang Y, Wang J, Liu C, Yin L, Li Y, Ji C, Zhou M, Zhou M, **Hu Q***. Targeting P2Y14R alleviates platelet-induced NET formation and venous thrombosis through PKA/AKAP13/RhoA axis. *Eur Heart J*. (2025)
2. Zhou M, Li Y, Qian J, Dong X, Guo Y, Yin L, Liu C, Hao K, **Hu Q***. P2Y14R activation facilitates liver regeneration via CREB/DNMT3b/Dact-2/ β -Catenin signals in acute liver failure. *Acta Pharm Sin B*. (2025)

CV: Qinghua Hu,

3. Guo Y, Mao T, Fang Y, Wang H, Yu J, Zhu Y, Shen S, Zhou M, Li H, **Hu Q***. Comprehensive insights into potential roles of purinergic P2 receptors on diseases: Signaling pathways involved and potential therapeutics. *J Adv Res*.(2025)
4. Li C, Wang H, Liu L, Liu C, Wang Y, Yin L, Yang Y, Tian S, Qian J, Zhou M, Li H, **Hu Q***. Discovery of Novel P2Y₁₄R Inhibitors for Ameliorating Liver Fibrosis by Suppressing Hepatic Stellate Cell Activation. *J Med Chem*.(2025)
5. Yin L, Ni K, Mao T, Tian S, Liu C, Chen J, Zhou M, Li H, **Hu Q***. Attributes novel drug candidate: Constitutive GPCR signal bias mediated by purinergic receptors. *Pharmacol Ther*. (2025)
6. Li Y, Zhou M, Li H, Dai C, Yin L, Liu C, Li Y, Zhang E, Dong X, Ji H, **Hu Q***. Macrophage P2Y₆ receptor deletion attenuates atherosclerosis by limiting foam cell formation through phospholipase C β /store-operated calcium entry/calreticulin/scavenger receptor A pathways. *Eur Heart J*. (2024)
7. Liu C, Wang H, Han L, Zhu Y, Ni S, Zhi J, Yang X, Zhi J, Sheng T, Li H, **Hu Q***. Targeting P2Y₁₄R protects against necroptosis of intestinal epithelial cells through PKA/CREB/RIPK1 axis in ulcerative colitis. *Nat Commun*. (2024)
8. Yin L, Zhang E, Mao T, Zhu Y, Ni S, Li Y, Liu C, Fang Y, Ni K, Lu Y, Li H, Zhou M, **Hu Q***. Macrophage P2Y₆R activation aggravates psoriatic inflammation through IL-27-mediated Th1 responses. *Acta Pharm Sin B*. (2024)
9. Zhu Y, Zhou M, Cheng X, Wang H, Li Y, Guo Y, Wang Y, Tian S, Mao T, Zhang Z, Li D, **Hu Q***, Li H. Discovery of Selective P2Y₆R Antagonists with High Affinity and In Vivo Efficacy for Inflammatory Disease Therapy. *J Med Chem*. (2023)
10. Wang Y, Zhou M, Ye T, Wang P, Lu R, Wang Y, Liu C, Xiao W, Li J, Meng Z, Xu L, **Hu Q***, Jiang C. Discovery of a Series of 5-Amide-1H-pyrazole-3-carboxyl Derivatives as Potent P2Y₁₄R Antagonists with Anti-Inflammatory Characters. *J Med Chem*. (2022)

Authorized Chinese Invention Patents

1. Cyclobutenedione-based Quinoxaline Compounds, Their Preparation Methods, Pharmaceutical Compositions, and Applications.(Inventors: **Qinghua Hu**, Huanqiu Li, et al.; Patent No.: ZL202310963192.5; Grant Date: 2025-02-07)
2. Benzoxazole Compounds, Their Preparation Methods, Pharmaceutical Compositions, and Applications.(Inventors: **Qinghua Hu**, Huanqiu Li, et al.; Patent No.: ZL202210174326.0; Grant Date: 2023-06-20)
3. Use of Lobetyolin in the Preparation of Drugs for Treating Diabetes.(Inventors: **Qinghua Hu**, Huanqiu Li, et al.; Patent No.: ZL202110908166.3; Grant Date: 2022-09-23)
4. A Benzofuran-Based Small Molecule P2Y₁₄ Receptor Inhibitor, Its Preparation and Application.(Inventors: **Qinghua Hu**, Huanqiu Li, et al.; Patent No.: ZL201911011418.1; Grant Date: 2022-05-20)
5. Use of Methyl 2,2'-(4-Carboxyoctanamido)dibenzoate in the Preparation of Drugs for Treating Inflammatory Diseases.(Inventors: **Qinghua Hu**, Huanqiu Li, et al.; Patent No.:

ZL201811507809.8; Grant Date: 2020-04-07; Transferred, contract value: 20 million RMB)

PRESENTATIONS

World Congress on Purines, Chengdu, Forum Report Sep 2025
13th Anti-inflammatory and Immunopharmacology Academic Conference, Dec 2023
Chongqing, Plenary Lecture
2023 National Conference on Cardiovascular Pharmacology, Zhuhai, Plenary Dec 2023
Lecture
The 6th Academic Symposium of the Metabolism Biology Branch of the Chinese Jul 2023
Biophysical Society, Zhengzhou, Forum Report on Immunometabolism
"National Rejuvenation Through Our Efforts" China Medicinal Port Sep 2022
Biopharmaceutical Summit Forum, Lianyungang, Plenary Lecture
2021 National Conference on Cardiovascular Pharmacology, Guangzhou, Plenary Nov 2021
Lecture
The 6th APS Frontiers Forum and the 15th Youth Pharmacy Forum of the Chinese Nov 2020
Pharmaceutical Association, Yantai, Expert Lecture